-
  bevictor伟德官网

  您现在的位置首页 > 师资队伍

 

 

个人信息

姓名:郭军

学历:博士

职称:教授

E-mailjguo@ccnu.edu.cn

 

教育与研究经历

1990-1994 武汉大学,化学学士

1994-1997 中国科学院福建物质结构研究所,物理化学硕士

1998-2002 英国谢菲尔德大学,有机化学博士

2002-2011 英国杜伦大学及美国佐治亚大学,博士后及研究专职

 

研究领域与兴趣

1. 抗肿瘤疫苗或抗病原体疫苗的设计、制备及免疫性质评估

2. 用于免疫治疗的生物大分子及化学小分子合成、修饰和性质

 

 

承担项目与课题信息

国家自然科学基金、科技部等项目课题

 

学术成果(代表性论文)

(1) MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern. J. Med. Chem. 2022, 65, 3563-3574.

(2) Self-Adjuvanting Lipoprotein Conjugate alphaGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern. J. Med. Chem. 2022, 65, 2558–2570.

(3) Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine. Front. Immunol. 2022, 13, 857779.

(4) A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern. Chem. Commun. 2022, 58, 3925-3928.

(5) RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern. Chem. Commun. 2022, 58, 2120-2123.

(6) MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide. Front. Chem. 2022, 10, 814880.

(7) Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern. ACS Infect Dis. 2022, 8, 1367-1375.